Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare Activity
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) anticipates
Catalyst Pharmaceuticals Announces Issuance Of Mandate By U.S. Court of Appeals For 11th Circuit Directing The District Court Judge In Co’s Lawsuit Against The FDA To Grant Summary Judgement In Favor of Catalyst
Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients
Catalyst Pharmaceuticals Announces DyDo Pharma Initiation Of A Phase 3 Study For FIRDAPSE In Japan
Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for
If You Invested $1,000 In Catalyst Pharmaceuticals Stock One Year Ago, Here’s How Much You’d Have Now
Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 ETF Trust (NYSE: SPY) total return over the last 12 months is 29.5%. But there is no question some big-name stocks performed better than others along the way.
Catalyst Pharmaceuticals Q3 Adj. EPS $0.14 Beats $0.10 Estimate, Sales $35.90M Beat $34.59M Estimate
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.10 by 40 percent. This is a 7.69 percent increase over earnings of $0.13 per share
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
Catalyst Pharmaceuticals Stock Reaches Resistance Level, Looks Ready To Break Out
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) shares are trading higher Wednesday although there looks to be no company-evident news to explain the jump in price. The stock is trading on above-average volume and trending on social media sites.